by newsworm | Mar 7, 2025 | Cipla, Pharma
The article focuses on Cipla Ltd. (NSE:CIPLA), a Indian pharmaceutical company, and its financial performance, specifically its Return on Equity (ROE). The ROE measures a company’s ability to generate profits from its shareholders’ investment.... by newsworm | Mar 3, 2025 | Cipla, Pharma
I’ve summarized the content for you: Cipla Hiring Diploma Candidates at StudyCafe Cipla, a well-known Indian multinational pharmaceutical company, is expanding its team and hiring diploma candidates through StudyCafe. StudyCafe is a popular platform that offers... by newsworm | Mar 2, 2025 | Cipla, Pharma
The CEO of Cipla, a major Indian pharmaceutical company, has expressed concerns that the increasing reliance on tariffs to dictate business decisions in the industry is not a sustainable or effective approach. In an interview, Dr. Samot Shergill, CEO of Cipla,... by newsworm | Feb 28, 2025 | Aurobindo Pharma, Biocon, Cipla, Lupin, Pharma, Sun Pharma
Kotak Institutional Equities has released a report on the potential impact of US tariffs on the pharmaceutical industry, particularly on Indian companies that supply generic and biosimilar drugs to the US market. The brokerage firm believes that high tariffs above 10%... by newsworm | Feb 20, 2025 | Alkem, Aurobindo Pharma, Biocon, Cipla, Lupin, Natco, Pharma, Sun Pharma, Torrent Pharma, Zydus
India’s top pharmaceutical companies delivered a mixed performance in the third quarter of fiscal 2025, with revenue growing 9% year-on-year and EBITDA and net profit rising 13% and 17%, respectively. Among the top performers were Lupin, Cipla, Sun Pharma, and...